Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2020 | 06-2020 | |
| Sales | 1,323 | 1,576 |
| Cost of Goods | 715 | 180 |
| Gross Profit | 608 | 1,396 |
| Operating Expenses | 157,864 | 116,029 |
| Operating Income | -156,541 | -114,453 |
| Other Income | 103,754 | 107,697 |
| Pre-tax Income | -52,787 | -6,756 |
| Income Tax | 711 | 1,221 |
| Net Income Continuous | -53,498 | -7,977 |
| Minority Interests | -18,100 | -4,734 |
| Net Income | $-35,398 | $-3,243 |
| EPS Basic Total Ops | -0.06 | -0.02 |
| EPS Basic Continuous Ops | -0.09 | -0.04 |
| EPS Diluted Total Ops | -0.06 | -0.02 |
| EPS Diluted Continuous Ops | -0.09 | -0.04 |
| EBITDA(a) | $-156,541 | $-114,453 |